These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34779063)

  • 21. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
    Alexis A; de Bruin-Weller M; Weidinger S; Soong W; Barbarot S; Ionita I; Zhang F; Valdez H; Clibborn C; Yin N
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
    Simpson EL; Silverberg JI; Nosbaum A; Winthrop K; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Fan H; Farooqui SA; Chan G; Alderfer J; Romero W; Chittuluru K
    Am J Clin Dermatol; 2024 Jul; 25(4):639-654. PubMed ID: 38888681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 24. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
    Reich K; Silverberg JI; Papp KA; Deleuran M; Katoh N; Strober B; Beck LA; de Bruin-Weller M; Werfel T; Zhang F; Biswas P; DiBonaventura MD; Chan G; Johnson S; Farooqui SA; Kerkmann U; Clibborn C
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2056-2066. PubMed ID: 37335885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H
    Immunotherapy; 2022 Jan; 14(1):5-14. PubMed ID: 34775830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.
    Schmid-Grendelmeier P; Gooderham MJ; Hartmann K; Konstantinou GN; Fellmann M; Koulias C; Clibborn C; Biswas P; Brunner PM
    Allergy; 2024 Jan; 79(1):174-183. PubMed ID: 37988255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
    Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abrocitinib may improve itch and quality of life in patients with itch-dominant atopic dermatitis.
    Silverberg JI; Thyssen JP; Lazariciu I; Myers DE; Güler E; Chovatiya R
    Skin Health Dis; 2024 Aug; 4(4):e382. PubMed ID: 39104653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type.
    Alexis AF; Silverberg JI; Rice ZP; Armstrong AW; Desai SR; Fonacier L; Kabashima K; Biswas P; Cella RR; Chan GL; Levenberg M
    Ann Allergy Asthma Immunol; 2024 Mar; 132(3):383-389.e3. PubMed ID: 37949351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
    Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
    Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost per responder analysis of abrocitinib versus dupilumab in moderate to severe atopic dermatitis.
    Maurelli M; Girolomoni G; Gisondi P
    Ital J Dermatol Venerol; 2024 Sep; ():. PubMed ID: 39250163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
    Drucker AM; Morra DE; Prieto-Merino D; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
    JAMA Dermatol; 2022 May; 158(5):523-532. PubMed ID: 35293977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
    Simpson EL; Prajapati VH; Leshem YA; Chovatiya R; de Bruin-Weller MS; Ständer S; Pink AE; Calimlim BM; Lee WJ; Teixeira H; Ladizinski B; Hu X; Yang Y; Liu Y; Liu M; Grada A; Platt AM; Silverberg JI
    Dermatol Ther (Heidelb); 2024 May; 14(5):1127-1144. PubMed ID: 38696027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
    Blauvelt A; Boguniewicz M; Brunner PM; Luna PC; Biswas P; DiBonaventura M; Farooqui SA; Rojo R; Cameron MC
    J Dermatolog Treat; 2022 Aug; 33(5):2605-2613. PubMed ID: 35763326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
    Blauvelt A; Silverberg JI; Lynde CW; Bieber T; Eisman S; Zdybski J; Gubelin W; Simpson EL; Valenzuela F; Criado PR; Lebwohl MG; Feeney C; Khan T; Biswas P; DiBonaventura M; Valdez H; Cameron MC; Rojo R
    J Am Acad Dermatol; 2022 Jan; 86(1):104-112. PubMed ID: 34416294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials.
    Meher BR; Mohanty RR; Padhy BM
    J Dermatolog Treat; 2022 Jun; 33(4):2335-2343. PubMed ID: 34315323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
    Kim BS; Silverberg JI; Ständer S; Yosipovitch G; Simpson EL; DiBonaventura M; Kerkmann U; Farooqui SA; Biswas P; Valdez H; Cameron MC
    Dermatitis; 2021 Oct; 32(1S):S39-S44. PubMed ID: 34175862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
    Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
    Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
    Drucker AM; Lam M; Elsawi R; Prieto-Merino D; Malek R; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
    Br J Dermatol; 2024 Jan; 190(2):184-190. PubMed ID: 37831594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.